Impact of Cilostazol on results of Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Lower Limb Ischemia admitted to Ahwaz Golestan hospital vascular surgery ward

The study aim was evaluation of cilostazol effects on results of balloon angioplasty for infrapopliteal artery disease

This randomized controlled clinical trial study was performed on 50 patients undergoing below the knee balloon angioplasty . Patients were randomly assigned into two groups of plavix alone (Group A) and plavix and cilostazol (Group B) and during the 3 month period , limb salvage , need for endovascular re-treatment , improvement of clinical symptoms and incidence of adverse effects were compared

There was no significant difference between the two groups in terms of demographic and clinical characteristics (P >0.05). Significant improvement of symptoms were observed in group B including improvement of rest pain and intermittent claudication within 3 months after treatment (P <0.05). Need for surgical intervention in group A was higher than group B in three months after treatment but there was no significant difference (P >0.05). None of the patients had reported heart failure within three months of treatment.

Although cilostazol administration after below the knee balloon angioplasty in patients with lower limb ischemia has a positive effect on improvement of symptoms such as improvement of rest pain and intermittent claudication But cilostazol did not show a positive effect on limb salvage, ischemic wound healing, and need for reintervention. The results of this study also showed that there was no significant difference in cilostazol users with cardiac complications and gastrointestinal bleeding.